CORRECTION -- Myovant Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Myovant Sciences (NYSE: MYOV) announced an update correcting the presentation time for CEO David Marek at the 39th Annual J.P. Morgan Healthcare Conference. The presentation will take place on January 12, 2021, at 2:50 p.m. Eastern Time, not Pacific Time as previously stated. This event aims to showcase Myovant's commitment to redefining healthcare for women and men, particularly through its lead product, relugolix, approved for advanced prostate cancer. A live webcast will be available on their website.

BASEL, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Myovant Sciences (NYSE: MYOV), please note that in the first paragraph of the release, the presentation time should be 2:50 p.m. Eastern Time, not 2:50 p.m. Pacific Time as previously stated. The corrected release follows:

Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that David Marek, chief executive officer of Myovant Sciences, Inc., will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 2:50 p.m. Eastern Time.

A live webcast of the presentation will be accessible on the Events page under the Investors & Media section of the Myovant website at www.myovant.com.

About Myovant Sciences 
Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Our lead product candidate, relugolix, is a once-daily, oral GnRH receptor antagonist. Relugolix (120 mg) is FDA-approved as ORGOVYX™ for adult patients with advanced prostate cancer. Relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. We are also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is our majority shareholder. For more information, please visit our website at www.myovant.com. Follow @Myovant on Twitter and LinkedIn.

Investor Contact:
Ryan Crowe
Vice President, Investor Relations
Myovant Sciences, Inc.
+1 (650) 781-9106
investors@myovant.com

Media Contact:
Albert Liao 
Director, Corporate Communications
Myovant Sciences, Inc.
+1 (650) 410-3055
media@myovant.com

FAQ

What time will Myovant Sciences present at the J.P. Morgan Healthcare Conference?

Myovant Sciences will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 2:50 p.m. Eastern Time.

Where can I watch the Myovant Sciences conference presentation?

You can watch the live webcast of Myovant Sciences' presentation on their Investors & Media Events page at www.myovant.com.

What is Myovant Sciences' lead product?

Myovant Sciences' lead product is relugolix, which is FDA-approved as ORGOVYX™ for adult patients with advanced prostate cancer.

What other products is Myovant Sciences developing?

Myovant Sciences is developing a combination tablet for uterine fibroids and MVT-602 for female infertility.

Who is the CEO of Myovant Sciences?

The CEO of Myovant Sciences is David Marek.